Log in

NASDAQ:CHRS - Coherus Biosciences Stock Price, Forecast & News

$19.35
+0.16 (+0.83 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$17.64
Now: $19.35
$19.68
50-Day Range
$17.39
MA: $19.91
$22.53
52-Week Range
$12.95
Now: $19.35
$23.91
Volume2.25 million shs
Average Volume1.12 million shs
Market Capitalization$1.36 billion
P/E Ratio16.26
Dividend YieldN/A
Beta3.16
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$356.07 million
Book Value($0.57) per share

Profitability

Net Income$-209,340,000.00

Miscellaneous

Employees232
Market Cap$1.36 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.


Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) announced its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.68 by $0.12. The biotechnology company had revenue of $123.86 million for the quarter, compared to analyst estimates of $123.60 million. View Coherus Biosciences' Earnings History.

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Coherus Biosciences.

What price target have analysts set for CHRS?

7 brokers have issued 12 month target prices for Coherus Biosciences' stock. Their forecasts range from $27.00 to $43.00. On average, they anticipate Coherus Biosciences' share price to reach $32.86 in the next year. This suggests a possible upside of 69.8% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.

What is the consensus analysts' recommendation for Coherus Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.

Has Coherus Biosciences been receiving favorable news coverage?

News coverage about CHRS stock has been trending very negative on Saturday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Coherus Biosciences earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Coherus Biosciences.

Are investors shorting Coherus Biosciences?

Coherus Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 10,770,000 shares, an increase of 7.2% from the January 15th total of 10,050,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is presently 10.4 days. Approximately 16.9% of the shares of the company are sold short. View Coherus Biosciences' Current Options Chain.

Who are some of Coherus Biosciences' key competitors?

What other stocks do shareholders of Coherus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Intelsat (I), Exelixis (EXEL), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Fossil Group (FOSL) and Sangamo Therapeutics (SGMO).

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the folowing people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
  • Dr. Peter K. Watler, Chief Technical Officer (Age 57)
  • Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Temasek Holdings Private Ltd (10.53%), State Street Corp (4.97%), Lord Abbett & CO. LLC (4.38%), Alliancebernstein L.P. (3.11%), UBS Asset Management Americas Inc. (2.73%) and Goldman Sachs Group Inc. (2.02%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Institutional Ownership Trends for Coherus Biosciences.

Which major investors are selling Coherus Biosciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Partner Fund Management L.P., First Trust Advisors LP, Chartwell Investment Partners LLC, Credit Suisse AG, 361 Capital LLC, PNC Financial Services Group Inc. and Russell Investments Group Ltd.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Insider Buying and Selling for Coherus Biosciences.

Which major investors are buying Coherus Biosciences stock?

CHRS stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Temasek Holdings Private Ltd, State Street Corp, Hawk Ridge Capital Management LP, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., Charles Schwab Investment Management Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Coherus Biosciences.

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $19.35.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $1.36 billion and generates $1.56 million in revenue each year. The biotechnology company earns $-209,340,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.View Additional Information About Coherus Biosciences.

What is Coherus Biosciences' official website?

The official website for Coherus Biosciences is http://www.coherus.com/.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  353 (Vote Underperform)
Total Votes:  721
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel